Becton, Dickinson and Company (BDX) has emerged as a leading figure in healthcare and consistently grabbed investor interest. Sweden's
Swedbank AB and the
Czech National Bank raised their holdings, with
Mn Services Vermogensbeheer B.V. and
Goldman Sachs also entering the play. This reinforces BDX's long-term growth prospects. Importantly, BDX has also secured a
$2.75 billion revolving credit facility. Despite a mix of divestments and acquisitions, strong Q3 results have spurred an optimistic case for investment. Evaluation enhancements post-Q3 figures heighten this case, with target prices from analysts hitting up to
$230.00. Notably, BDX sold close to a thousand shares, underlining shareholder trust. Further, their Biosciences & Diagnostic Solutions business combined with Waters to make a life science and diagnostic leader for regulated, high-volume testing. Q3's surprising outperformance and subsequent EPS growth, as well as a partnership decision to become the first in MedTech to earn
HIRC's Diamond Badge, continue to bolster their market position. Lastly, BDX plans to boost US manufacturing of critical medical devices, invest
$35 million in a Nebraska facility, expand the Rotarex™ Atherectomy System in peripheral artery disease treatment, and has received FDA clearance for a rapid COVID-19 test.
Becton Dickinson and BDX News Analytics from Wed, 15 Jan 2025 08:00:00 GMT to Sat, 20 Sep 2025 16:21:34 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 2
